Strategic partnerships Eurofins Discovery actively engages in strategic collaborations (e.g., GPCR partnership with Dr. GPCR CORP, Dompé collaboration leveraging AI platforms, and new client wins like Awakn Life Sciences). This indicates sales opportunities through co-developed programs, integrated services, and cross-promotional initiatives with AI, supercomputing, and specialized CRO partners.

AI and NAMs With the launch of DiscoveryAI SAFIRE and focus on New Approach Methodologies (NAMs) and AI-driven drug discovery, there is a sales opening to offer advanced in silico tools, ADMET prediction services, and AI-assisted screening to accelerate preclinical programs for biotech, pharma, and biotech-enabled startups.

Integrated platform The combination of DiscoveryOne capabilities, Beacon Discovery integration, and turnkey drug discovery services positions Eurofins Discovery as a one-stop provider. Sales opportunities exist in offering bundled or end-to-end discovery solutions to customers seeking streamlined pathways from target validation to preclinical candidates.

Global reach With a global team and partnerships across Europe and the US, Eurofins Discovery can target multinational programs and distribute pilots or scale-up collaborations regionally, appealing to global sponsors seeking consistent CRO support across sites.

Funding and growth signals Revenue in the mid-range and ongoing expansions through acquisitions and new clients signal growth potential. This suggests opportunities to upsell expanded testing methods, tools, and AI-enabled services to existing clients and to pursue new programs in oncology, neuroscience, and other high-demand therapeutic areas.